Archives
Please, enter cell line, author or any other phrase or word you would like to search for.
Fighting cancer at an early stage
Using nanoparticles and HoloMonitor technology Prof. Anette Gjörloff Wingren and her team aim to develop an early screening method that detects cancer by a simple blood test.
PHI´s new software available for customer delivery
In this first version of App Suite three common analyzes are included: cell proliferation, cell motility, and cell quality control. App Suite will be rapidly expanded with additional applications. HoloMonitor® App Suite 2.0 is scheduled to be released to customers in Q4 2018.
Kommuniké från extra bolagsstämma i Phase Holographic Imaging PHI AB (publ)
Igår, den 18 juni 2018, hölls extra bolagsstämma i Phase Holographic Imaging PHI AB (publ). Stämman röstande enhälligt för föreslagna beslut gällande nyemission.
PHI and BioSpherix sign co-marketing agreement
Phase Holographic Imaging (PHI) and BioSpherix recently signed a collaboration agreement aiming to co-market the companies’ complementary product lines. BioSpherix, NY USA, manufactures and markets advanced cell incubators.
Biostock interview with CEO Peter Egelberg
New CEO commentary — “Redefining aging with HoloMonitor”
In the CEO commentary “Redefining aging with HoloMonitor” Peter Egelberg comments on the promising research results that were recently reported by Australian television.
PHI at the Nordic Microscopy Society meeting, June 25-28
The Nordic Microscopy Society meeting in Lyngby Denmark offers several opportunities to meet with us and to hear about the latest HoloMonitor news.
We believe we’ve found the Holy Grail
We believe we’ve found the Holy Grail” Associate Professor Derek Richard, at Queensland University of Technology in Australia, has, with help from HoloMonitor M4, found a way to turn back time and make old cells young again.
Notice of Extraordinary General Meeting in Phase Holographic Imaging PHI AB (publ)
Notice to the shareholders in Phase Holographic Imaging AB (publ), 556542-7811, to attend an Extraordinary General Meeting on Monday June 18 at 06.00 PM (18.00) at PHI’s office, Scheelevägen 22, Lund.
Decision on rights issue for continued growth, establishment of sales organization and commercial break-through
The Board of directors of Phase Holographic Imaging PHI AB (publ) (”PHI”) has decided to conduct a rights issue of units, which is subject to approval on Extraordinary General Meeting, that can provide the company a total of SEK 64.6 million at the most prior to issuing costs.